Back to Search
Start Over
Two cases of bacterial meningitis due to meropenem-resistant Streptococcus pneumoniae: A threat of serotype 35B, ST 558 lineage.
- Source :
-
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy [J Infect Chemother] 2020 Jul; Vol. 26 (7), pp. 745-748. Date of Electronic Publication: 2020 Mar 12. - Publication Year :
- 2020
-
Abstract
- Although the pneumococcal conjugate vaccine (PCV) has decreased the incidence of invasive pneumococcal disease (IPD) in children, cases of IPD caused by non-PCV serotypes have been increasing. Here, we report two cases of bacterial meningitis caused by meropenem-resistant Streptococcus pneumoniae; in both the cases, 13-valent PCV (PCV13) had been administered. The isolated S. pneumoniae strains were non-PCV13 serotype 35B and resistant to penicillin G, cefotaxime, and meropenem. In addition, multilocus sequence typing (MLST) revealed the sequence type (ST) to be 558. In case 1, a 6-month-old girl recovered without sequelae after antibiotic therapy comprising cefotaxime and vancomycin, whereas in case 2, a 9-month-old boy was treated with an empirical treatment comprising ceftriaxone and vancomycin administration. However, maintaining the blood concentration of vancomycin within the effective range was difficult, due to which the antibiotics were changed to panipenem/betamipron. During the treatment, he presented with seizures, which were effectively controlled with antiepileptic drugs. The rate of incidence of penicillin-susceptible IPD has been substantially increasing after the introduction of PCV. However, an upsurge in IPD cases due to multidrug-resistant (MDR) serotype 35B has been reported in countries where PCV13 was introduced before introducing in Japan. Moreover, an increase in the proportion of MDR serotype 35B and decrease in the susceptibility to broad-spectrum antimicrobials, including meropenem, have been reported. Hence, the number of meningitis cases caused by MDR serotype 35B/ST558 may increase in the future.<br />Competing Interests: Declaration of Competing Interest None.<br /> (Copyright © 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.)
- Subjects :
- Anti-Bacterial Agents therapeutic use
Cefotaxime pharmacology
Cefotaxime therapeutic use
Female
Humans
Infant
Male
Meningitis, Pneumococcal blood
Meningitis, Pneumococcal diagnosis
Meningitis, Pneumococcal microbiology
Meropenem therapeutic use
Microbial Sensitivity Tests
Multilocus Sequence Typing
Pneumococcal Vaccines administration & dosage
Serotyping
Streptococcus pneumoniae drug effects
Streptococcus pneumoniae isolation & purification
Thienamycins pharmacology
Thienamycins therapeutic use
Treatment Outcome
beta-Alanine analogs & derivatives
beta-Alanine pharmacology
beta-Alanine therapeutic use
Anti-Bacterial Agents pharmacology
Drug Resistance, Multiple, Bacterial genetics
Meningitis, Pneumococcal drug therapy
Meropenem pharmacology
Streptococcus pneumoniae genetics
Subjects
Details
- Language :
- English
- ISSN :
- 1437-7780
- Volume :
- 26
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
- Publication Type :
- Academic Journal
- Accession number :
- 32171658
- Full Text :
- https://doi.org/10.1016/j.jiac.2020.02.013